SIGLEC8 Polyclonal Antibody

活动价:

¥680.00

市场价:¥880.00

一键复制产品信息
产品规格:
  • 50μL
  • 100μL
货号:

FAB2617101

  • 产品信息
  • 注意事项
  • 实验验证
  • 产品声明
  • 引用文献
  • 相关产品
  • 文件下载
商品描述
  • 靶点-Target

    SIGLEC8

  • 反应性

    Human

  • 应用

    WB,ELISA

  • 宿主物种-Host Species

    Rabbit

  • 同种型-Isotype

    IgG

  • 修饰-Modification

    Unmodified

  • MW(Observed)

    50kD

  • 推荐稀释比

    WB 1:500-1:2000;ELISA 1:20000;Not yet tested in other applications.

  • 组成

    Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

  • 纯化工艺

    The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

  • 储存

    -15°C to -25°C/1 year(Do not lower than -25°C)

  • 浓度

    1 mg/ml

  • 克隆性

    Polyclonal

  • 免疫原

    The antiserum was produced against synthesized peptide derived from the Internal region of human SIGLEC8. AA range:81-130

  • 特异性

    CD329 Polyclonal Antibody detects endogenous levels of CD329 protein.

  • 基因名称

    SIGLEC8

  • 蛋白名称

    Sialic acid-binding Ig-like lectin 8

  • 别名

    SIGLEC8;SAF2;Sialic acid-binding Ig-like lectin 8;Siglec-8;CDw329;Sialoadhesin family member 2;SAF-2;CD329

  • Organism-1

    Human

  • 基因ID-1

    27181

  • SwissProt-1

    Q9NYZ4

  • 背景

    Sialic acid-binding immunoglobulin (Ig)-like lectins, or SIGLECs (e.g., CD33 (MIM 159590)), are a family of type 1 transmembrane proteins each having a unique expression pattern, mostly in hemopoietic cells. SIGLEC8 is a member of the CD33-like subgroup of SIGLECs, which are localized to 19q13.3-q13.4 and have 2 conserved cytoplasmic tyrosine-based motifs: an immunoreceptor tyrosine-based inhibitory motif, or ITIM (see MIM 604964), and a motif homologous to one identified in signaling lymphocyte activation molecule (SLAM; MIM 603492) that mediates an association with SLAM-associated protein (SAP; MIM 300490) (summarized by Foussias et al., 2000 [PubMed 11095983]).[supplied by OMIM, May 2010],

  • 细胞定位

    Membrane; Single-pass type I membrane protein.